Citations 12
QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.
Miller, David S. , Cloven, Noelle, Hendrickson, Andrea E. Wahner , DiSilvestro, Paul , Cristea, Mihaela , Berek, Jonathan S. , Chan, John K. , Clark, Romnee, Matulonis, Ursula A. , Monk, Bradley J. , Miller, David S , Moore, Kathleen N. , Secord, Angeles Alvarez , Geller, Melissa Ann , Fleming, Gini F. , Azodi, Masoud , Oza, Amit M. , Li, Yong
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5514-5514
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Barry, William T., Wenham, Robert M. , Hendrickson, Andrea E. Wahner , Armstrong, Deborah K. , Chan, Nancy , Lee, Jung‐Min , Penson, Richard T. , Cristea, Mihaela , Abbruzzese, James L. , Matsuo, Koji , Olawaiye, Alexander , Farooq, Sarah , Kohn, Elise C. , Matulonis, Ursula A. , Liu, Joyce F. , Cohn, David E. , Swisher, Elizabeth M. , Van Allen, Eliezer M , Shapiro, Geoffrey I. , Ivy, S. Percy
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5519-5519